🧠 What does Insulet do anyway?

Insulet $PODD (+0,74 %) develops the Omnipod system - a tubeless insulin pump for diabetics.

👉 Advantage:

• No classic tube
• Easier in everyday life
• Particularly popular with younger patients

💡 The trend is clearly moving towards automated diabetes therapy (keyword: artificial pancreas)

📊 Figures that are convincing

• 📈 Sales growth: ~20-30% per year
• 💰 Turnover: over 1.5+ billion USD
• 📊 Gross margin: ~65-70%
• 🌍 Market: growing strongly worldwide (diabetes is on the rise)

👉 Important:

The addressable market is huge and growing every year

🚀 Why could the share continue to rise?

✅ More diabetes patients worldwide

✅ Trend towards modern technology (pumps instead of syringes)

✅ Recurring income (pods have to be constantly repurchased!)

✅ Strong market position in the "tubeless pumps" sector

👉 The business model is almost like a subscription model 💰

⚠️ Risks (of course there are risks)

• Competition from companies such as DexCom or Medtronic
• High valuation (not a bargain!)
• Dependence on innovation & approvals

🧭 My conclusion

👉 Insulet is not a hype play, but rather a long-term growth stock in the healthcare sector